What Do Analysts Recommend for Boston Scientific?
Let’s look at Wall Street analysts’ recommendations and target prices for Boston Scientific (BSX) over the next 12 months.
Boston Scientific has begun implementing the necessary fixes for its Lotus Valve system, and it expects to relaunch the product in the Europe and other international markets in 4Q17.
On May 9, 2017, Boston Scientific (BSX) announced the FDA approval of its Resonate family of products, including its ICD and CRT-D systems.
On May 17, 2017, Boston Scientific (BSX) announced the completion of its acquisition of Symetis, which it announced on March 30, 2017.
Lotus Valve systems are Boston Scientific’s (BSX) TAVR (transcatheter aortic valve replacement) range of devices. The device system is approved to be sold in Europe.
Boston Scientific (BSX) was trading at $27.2 on May 25, 2017. It had a 50-day moving average of $25.8 and a 200-day moving average of $23.9.
KMI stock is currently trading at a forward EV-to-EBITDA multiple of nearly 12x, which is lower than KMI’s five-year average multiple of ~17x.
Kinder Morgan (KMI) stock is currently trading 6.6% below its 50-day moving average and 10% below its 200-day moving average.
Based on its closing price of $19.42 on May 25, KMI stock could trade in between $19.95 and $18.89 over the next seven days.
Kinder Morgan intends to raise $1.75 billion Canadian dollars through the offering to partially fund its Trans Mountain expansion project.
Best Buy rose to record high price levels on May 25. Despite prevailing weakness in the retail sector, Best Buy posted upbeat first quarter results.
Sanofi Pasteur reported revenue growth of 22.2% at constant exchange rates to 784 million euros during 1Q17.
Revenues from Sanofi’s Established Prescription Products rose 0.6% at constant exchange rates during 1Q17 and reported revenues of ~2.6 billion euros in 1Q17.
Sanofi’s (SNY) Generics business contributes ~5% to the group’s total revenues.
Sanofi’s Diabetes and Cardiovascular franchise reported revenues of ~1.4 billion euros in 1Q17.
Sanofi Pasteur’s revenues rose 22.2 % at constant exchange rates to 784 million euros during 1Q17.
Sanofi (SNY) reported growth of over 15% at constant exchange rates in its 1Q17 revenues from Genzyme.
Paris-based Sanofi (SNY) reported revenues of ~8.7 billion euros in 1Q17. Sanofi surpassed analyst estimates, posting EPS of 1.42 euros in 1Q17, compared to estimates of 1.31 euros.
Coeur Mining (CDE) is trading at a forward EV-to-EBITDA multiple of 5.1x. That’s the lowest in its peer group.
In 1Q17, Coeur Mining’s free cash flow was $31.3 million, or $35.8 million higher than in 4Q16 and $56 million higher YoY.